The integration of these solutions will allow Eversense CGM data to be synced into Glooko’s platform directly from the Senseonics cloud. Eversense users will be able to view historical glucose and related data both in Glooko’s Mobile and Web Apps and will continue to get real-time readings from their Eversense Mobile Application. Healthcare professionals may view their patients’ data in the Glooko Population Tracker in interactive reports alongside other data resident in Glooko.
“With this integration, users can consolidate their glucose data with insulin, meals, medication and exercise to help them see glycemic patterns more readily. Glooko allows our users to take full advantage of both companies’ platforms and the large amount of data from our Eversense and Eversense XL systems,” said Dr. Tim Goodnow, president and CEO of Senseonics. “Partnering with a platform like Glooko fits with our strategy of giving people the tools to use all of their health data to conveniently and confidently make actionable lifestyle decisions.”
For Glooko, the integration of the Eversense systems is the first long-term sensor that will be compatible with their intelligent digital health platform. Users of the Eversense systems will have the opportunity to see how their glucose levels change over the long term without having to estimate the impact of frequent sensor changeovers and warm-up periods.
“We are thrilled to add Senseonics’ breakthrough Eversense and Eversense XL CGM data to our platform so that people with diabetes and clinicians can access this valuable data in context in our reports online and via mobile,” said Russ Johannesson, Glooko CEO. “Our cloud integration with Senseonics gives users easy access to their glucose data from the sensor, enabling them to make decisions based on their glucose patterns.”
The Eversense system has been integrated with Diasend in the European Union since 2017. The companies expect implementation of the Eversense/Glooko data integration to be by the end of the year. Learnings from this partnership will benefit both organizations as they expand into insulin titration and decision support tools.
This global agreement covers all markets where Glooko and the Eversense Systems are currently available.
The Eversense Continuous Glucose Monitoring System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 90 days. It is intended to complement, not replace, fingerstick blood glucose monitoring. The sensor insertion and removal is performed by a physician.
Senseonics Holdings Inc. designs, develops, and commercializes glucose monitoring products. Senseonics’ first-generation continuous glucose monitoring system, Eversense, includes a small sensor, smart transmitter and mobile application. Based on fluorescence sensing technology, the sensor is designed to be inserted subcutaneously and communicate with the smart transmitter to wirelessly transmit glucose levels to a mobile device. After insertion, the sensor is designed to continually and accurately measure glucose levels.
Glooko provides insights into diabetes by enabling both people with diabetes (PWDs) and their care teams with technology to understand and manage diabetes care. Its self-management mobile app automatically uploads data from devices including blood glucose meters, insulin pumps, CGMs and several fitness and activity trackers—providing timely and verified data and enabling PWDs and care teams to correlate it with diet, exercise, medication and other data. The company provides care teams with an office data upload solution and a population health app so they can support PWDs during and in-between office visits. Glooko products are used by 7,000 clinics and over 1.5 million PWDs in 23 countries across 15 languages.